Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Izokibep by Acelyrin for Hidradenitis Suppurativa: Likelihood of Approval
Izokibep is under clinical development by Acelyrin and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III...
Lonigutamab by Acelyrin for Graves' Ophthalmopathy: Likelihood of Approval
Lonigutamab is under clinical development by Acelyrin and currently in Phase II for Graves' Ophthalmopathy. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Acelyrin's Lonigutamab Ugodotin?
Lonigutamab Ugodotin is a monoclonal antibody commercialized by Acelyrin, with a leading Phase II program in Graves' Ophthalmopathy. According to...
VB-119 by Acelyrin for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
VB-119 is under clinical development by Acelyrin and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData,...